Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington’s Patients

Oxidative stress has long been implicated in the pathophysiology and progression of Huntington’s disease (HD). Uric acid (UA) is a naturally occurring antioxidant that is present in the brain and periphery. Growing evidence has implicated UA as a molecular biomarker for several neurodegenerative diseases, most notably Parkinson’s disease (PD). In this study, we investigated UA levels in clinical samples from HD patients and normal controls (NCs) and assessed potential relationships between UA levels and disease and clinical data. UA levels were measured in plasma (n = 107) and saliva (n = 178) samples from premanifest (pre-HD) and manifest HD patients and control subjects. Gender effects of UA levels were observed in both biofluids, with male patients showing higher UA levels compared to female patients. Comparisons of UA levels across diagnostic groups, separated by gender, revealed that both plasma and salivary UA levels were significantly lower in female pre-HD and manifest HD patients compared to NCs. Salivary levels of UA were also significantly lower in male manifest HD patients versus controls, but not in plasma. Correlations of peripheral UA levels to clinical data also showed differences according to gender. In male HD patients, both plasma and salivary UA levels were significantly negatively correlated with total functional capacity (TFC), while positive correlations were observed with total motor score (TMS). Female HD patients showed a significant positive correlation between plasma UA levels and TMS, while salivary UA levels from female patients were significantly correlated to disease burden. Finally, in a separate cohort, we show that UA levels are decreased in postmortem prefrontal cortical samples (n = 20) from HD subjects compared to matched controls. These findings suggest that decreased levels of UA in the brains of HD patients can be reflected in peripheral fluids, with salivary measures of UA particularly offering significant promise as a potentially relevant, non-invasive biomarker of disease symptoms and burden. Our findings further highlight the impact of sexual dimorphism in HD pathophysiology.

[1]  Juvenile Huntington disease , 2020, Definitions.

[2]  Aamir Ahmad,et al.  Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders , 2019, Neuroscience & Biobehavioral Reviews.

[3]  W. Tian,et al.  Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study , 2019, Aging Clinical and Experimental Research.

[4]  W. Zhou,et al.  Gender-specific association between uric acid level and chronic kidney disease in the elderly health checkup population in China , 2019, Renal failure.

[5]  J. Winderickx,et al.  A Mitochondria-Associated Oxidative Stress Perspective on Huntington’s Disease , 2018, Front. Mol. Neurosci..

[6]  Crystal I. Bryce,et al.  The validity, stability, and utility of measuring uric acid in saliva. , 2018, Biomarkers in medicine.

[7]  M. Vila,et al.  Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease , 2018, Front. Neurosci..

[8]  J. Corey-Bloom,et al.  Salivary levels of total huntingtin are elevated in Huntington’s disease patients , 2018, Scientific Reports.

[9]  A. Ascherio,et al.  Targeting urate to reduce oxidative stress in Parkinson disease , 2017, Experimental Neurology.

[10]  Y. Lee,et al.  Serum uric acid levels and hormone therapy type: a retrospective cohort study of postmenopausal women , 2017, Menopause.

[11]  Zhaokun Ma,et al.  Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis , 2017, PloS one.

[12]  L. Simoni,et al.  Sex and Gender Differences in Central Nervous System-Related Disorders , 2016, Neuroscience journal.

[13]  D. Mann,et al.  Novel Metabolite Biomarkers of Huntington's Disease As Detected by High-Resolution Mass Spectrometry. , 2016, Journal of proteome research.

[14]  F. Turkheimer,et al.  Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers , 2015, Neurobiology of Disease.

[15]  Zhanguo Li,et al.  The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout , 2015, International journal of rheumatic diseases.

[16]  Yih-Ru Wu,et al.  Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model , 2015, Brain, Behavior, and Immunity.

[17]  Xiaofeng Yang,et al.  A Double-edged Sword: Uric Acid and Neurological Disorders , 2013, Brain disorders & therapy.

[18]  Paul E. Gilbert,et al.  Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[19]  E. Kopel,et al.  Association of serum uric acid and cardiovascular disease in healthy adults. , 2013, The American journal of cardiology.

[20]  Nikolaus R. McFarland,et al.  Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders , 2013, Neurodegenerative Diseases.

[21]  H. Putter,et al.  The influence of gender on phenotype and disease progression in patients with Huntington's disease. , 2013, Parkinsonism & related disorders.

[22]  I. Ferreira,et al.  Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells. , 2012, Free radical biology & medicine.

[23]  D. Granger,et al.  Focus on methodology: salivary bioscience and research on adolescence: an integrated perspective. , 2012, Journal of adolescence.

[24]  F. Agakov,et al.  The Association of Dietary Intake of Purine-Rich Vegetables, Sugar-Sweetened Beverages and Dairy with Plasma Urate, in a Cross-Sectional Study , 2012, PloS one.

[25]  M. Schwarzschild,et al.  Urate in Parkinson’s Disease: More Than a Biomarker? , 2012, Current Neurology and Neuroscience Reports.

[26]  M. Beal,et al.  Antioxidants in Huntington's disease. , 2012, Biochimica et biophysica acta.

[27]  H. Zetterberg,et al.  Urate as a marker of development and progression in Parkinson's disease. , 2011, Drugs of today.

[28]  N. Aronin,et al.  Aberrant Rab11-Dependent Trafficking of the Neuronal Glutamate Transporter EAAC1 Causes Oxidative Stress and Cell Death in Huntington's Disease , 2010, The Journal of Neuroscience.

[29]  David M. Wilson,et al.  Stoichiometry of Base Excision Repair Proteins Correlates with Increased Somatic CAG Instability in Striatum over Cerebellum in Huntington's Disease Transgenic Mice , 2009, PLoS genetics.

[30]  V. Zissimopoulos,et al.  Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration , 2009, Clinical Neurology and Neurosurgery.

[31]  I. Schlesinger,et al.  Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[32]  A. Rodríguez-Malaver,et al.  Effects of Aerobic Exercise on Uric Acid, Total Antioxidant Activity, Oxidative Stress, and Nitric Oxide in Human Saliva , 2008, Research in sports medicine.

[33]  Yih-Ru Wu,et al.  Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. , 2007, Biochemical and biophysical research communications.

[34]  S. Tabrizi,et al.  Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.

[35]  L. Cardon,et al.  The Relationship Between CAG Repeat Length and Age of Onset Differs for Huntington's Disease Patients with Juvenile Onset or Adult Onset , 2007, Annals of human genetics.

[36]  C. McMurray,et al.  Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases , 2007, Neuroscience.

[37]  G. Rebec,et al.  Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease , 2007, Behavioural Brain Research.

[38]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[40]  D. Morens,et al.  Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. , 1996, American journal of epidemiology.

[41]  W. H. Church,et al.  Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation , 1994, Brain Research Bulletin.

[42]  M. Hayden,et al.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.

[43]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[44]  S. Paganoni,et al.  Urate as a Marker of Risk and Progression of Neurodegenerative Disease , 2016, Neurotherapeutics.

[45]  Barbara Schober,et al.  Sex and Gender Differences , 2012 .

[46]  J. Kaye,et al.  Uric acid as a CNS antioxidant. , 2010, Journal of Alzheimer's disease : JAD.

[47]  P Bailey,et al.  Double Edged Sword , 2002 .

[48]  M. Yaron,et al.  The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. , 2000, Arthritis and rheumatism.

[49]  M Kitamura,et al.  [Uric acid]. , 1967, Nihon rinsho. Japanese journal of clinical medicine.